Coadministration of the cyanobacterial lipopolysaccharide antagonist CyP with antibiotic inhibits cytokine production by an in vitro meningitis model infected with Neisseria meningitidis

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 5, 2012, Pages 1145-1154

  Oliver, Rebecca ^a   Staples, Karl J ^a   Heckels, John ^a   Rossetti, Carlo ^b   Molteni, Monica ^c   Christodoulides, Myron ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c Bluegreen Biotech Srl   (Italy)

Author keywords

Inflammation; Meningococcus; Oscillatoria planktothrix

Indexed keywords

ANTIINFLAMMATORY AGENT; CYANOBACTERIAL LIPOPOLYSACCHARIDE ANTAGONIST; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PENICILLIN G; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL MENINGITIS; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MENINGIOMA; NEISSERIA MENINGITIDIS; NONHUMAN;

ANTI-BACTERIAL AGENTS; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; EPITHELIAL CELLS; HUMANS; IMMUNOLOGIC FACTORS; LIPOPOLYSACCHARIDES; MACROPHAGES; MENINGITIS, MENINGOCOCCAL; NEISSERIA MENINGITIDIS; PENICILLIN G;

EID: 84859599041     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks031     Document Type: Article

References (41)

1. Christodoulides M, Heckels JE, Weller RO. The role of the leptomeninges in meningococcal meningitis. In: Ferreiros C, Criado MT, Vazquez J, eds. Emerging Strategies in the Fight Against Meningitis. Norfolk, UK: Horizon Press, 2002; 1-37.
2. Brandtzaeg P, Halstensen A, Kierulf P et al. Molecular mechanisms in the compartmentalized inflammatory response presenting as meningococcal meningitis or septic shock. Microb Path 1992; 13: 423-31.
3. Waage A, Halstensen A, Shalaby R. Local production of tumor necrosis factor a, interleukin 1 and interleukin 6 in meningococcal meningitis. J Exp Med 1989; 170: 1859-67.
4. Lopez-Cortes LF, Cruz-Ruiz M, Gomez-Mateos J et al. Interleukin-8 in cerebrospinal fluid from patients with meningitis of different etiologies -its possible role as neutrophil chemotactic factor. J Infect Dis 1995; 172: 581-4.
5. Lopez-Cortes LF, Cruz-Ruiz M, Gomez-Mateos J et al. Measurement of levels of tumor necrosis factor-a and interleukin-1b in the CSF of patients with meningitis of different etiologies: utility in the differential diagnosis. Clin Infect Dis 1993; 16: 534-9.
6. van Deuren M, van der Venjongekrijg J, Bartelink AKM et al. Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. J Infect Dis 1995; 172: 433-9.
7. van Deuren M, van der Venjongekrijg J, Vannier E et al. The pattern of interleukin-1β (IL-1β) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections. Blood 1997; 90: 1101-8.
8. Wells DB, Tighe PJ, Wooldridge KG et al. Differential gene expression during meningeal-meningococcal interaction: evidence for self-defense and early release of cytokines and chemokines. Infect Immun 2001; 69: 2718-22.
9. Fowler MI, Weller RO, Heckels JE et al. Different meningitis-causing bacteria induce distinct inflammatory responses on interaction with cells of the human meninges. Cell Micro 2004; 6: 555-67.
10. Brandtzaeg P, Bjerre A, Ovstebo R et al. Neisseria meningitidis lipopolysaccharides in human pathology. J Endotox Res 2001; 7: 401-20.
11. Zughaier SM, Tzeng YL, Zimmer SM et al. Neisseria meningitidis lipooligosaccharide structure-dependent activation of the macrophage CD14/Toll-like receptor 4 pathway. Infect Immun 2004; 72: 371-80.
12. Mirlashari MR, Hoiby EA, Holst J et al. Outer membrane vesicles from Neisseria meningitidis: effects on cytokine production in human whole blood. Cytokine 2001; 13: 91-7.
13. Moresco EM, LaVine D, Beutler B. Toll-like receptors. Curr Biol 2011; 21: R488-93.
14. Poltorak A, Ricciardi-Castagnoli P, Citterio S et al. Physical contact between lipopolysaccharide and Toll-like receptor 4 revealed by genetic complementation. Proc Natl Acad Sci USA 2000; 97: 2163-7.
15. Macagno A, Molteni M, Rinaldi A et al. A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression. J Exp Med 2006; 203: 1481-92.
16. Jemmett K, Macagno A, Molteni M et al. A cyanobacterial LPS-antagonist inhibits cytokine production induced by Neisseria meningitidis infection of a human whole blood model of septicaemia. Infect Immun 2008; 76: 3156-63.
17. Thorgersen EB, Macagno A, Rossetti C et al. Cyanobacterial LPS antagonist (CyP) -a novel and efficient inhibitor of Escherichia coli LPS-induced cytokine response in the pig. Mol Immunol 2008; 45: 3553-7.
18. Maio RC, Cosentino M, Rossetti C et al. Effect of the lipopolysaccharide antagonist Planktothrix sp. FP1 cyanobacterial extract on human polymorphonuclear leukocytes. Int Immunopharmacol 2011; 11: 194-8.
19. Keleti G, Sykora JL. Production and properties of cyanobacterial endotoxins. App Env Microbiol 1982; 43: 104-9.
20. Kahler CM, Stephens DS. Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endotoxin). Crit Rev Microbiol 1998; 24: 281-334.
21. Humphries HE, Triantafilou M, Makepeace BL et al. Activation of human meningeal cells is modulated by lipopolysaccharide (LPS) and non-LPS components of Neisseria meningitidis and is independent of Toll-like receptor (TLR)4 and TLR2 signalling. Cell Micro 2005; 7: 415-30.
22. Tichomirowa MA, Theodoropoulou M, Daly AF et al. Toll-like receptor-4 is expressed in meningiomas and mediates the antiproliferative action of paclitaxel. Int J Cancer 2008; 123: 1956-63.
23. Hardy SJ, Christodoulides M, Weller RO et al. Interactions of Neisseria meningitidis with cells of the human meninges. Mol Microbiol 2000; 36: 817-29.
24. McGuinness BT, Clarke IN, Lambden PR et al. Point mutation in meningococcal porA gene associated with increased endemic disease. Lancet 1991; 337: 514-7.
25. Zak K, Diaz JL, Jackson D et al. Antigenic variation during infection with Neisseria gonorrhoeae: detection of antibodies to surface proteins in sera of patients with gonorrhea. J Infect Dis 1984; 149: 166-73.
26. Williams JN, Skipp PJ, Humphries HE et al. Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant. Infect Immun 2007; 75: 1364-72.
27. Lambden PR, Heckels JE. Synthesis of immunogenic oligosaccharide-protein conjugates from the lipopolysaccharide of Neisseria gonorrhoeae p9. J Immunol Meth 1982; 48: 233-40.
28. Christodoulides M, Makepeace BL, Partridge K et al. Interaction of Neisseria meningitidis with human meningeal cells induces the secretion of a distinct group of chemotactic, pro-inflammatory and growth-factor cytokines. Infect Immun 2002; 70: 4035-44.
29. Stephens DS, Edwards KM, Morris FMG. Pili and outer membrane appendages on Neisseria meningitidis in the cerebrospinal fluid of an infant. J Infect Dis 1982; 146: 568.
30. Brandtzaeg P, Ovstebo R, Kierulf P. Compartmentalization of lipopolysaccharide production correlates with clinical presentation in meningococcal disease. J Infect Dis 1992; 166: 650-2.
31. Hieber JP, Nelson JD. A pharmacologic evaluation of penicillin in children with purulent meningitis. New Eng J Med 1977; 297: 410-3.
32. Sturrock RR. An electron microscopic study of macrophages in the meninges of the human embryonic optic nerve. J Anat 1988; 157: 145-51.
33. Steven N, Wood M. The clinical spectrum of meningococcal disease. In: Cartwright KAV, ed. Meningococcal Disease. Chichester: John Wiley & Sons, 1995; 178-205.
34. Brandtzaeg P, van Deuren M. Classification and pathogenesis of meningococcal infections. In: Christodoulides M, ed. Neisseria meningitidis: Advanced Methods and Protocols. New York: Humana Press, 2012; 21-35.
35. Levin M, Quint PA, Goldstein B et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet 2000; 356: 961-7.
36. Tidswell M, Tillis W, LaRosa SP et al. Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2010; 38: 72-83.
37. Christ WJ, Asano O, Robidoux ALC et al. E5531, a pure endotoxin antagonist of high potency. Science 1995; 268: 80-3.
38. Halstensen A, Ceska M, Brandtzaeg P et al. Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease. J Infect Dis 1993; 167: 471-5.
39. Waage A, Halstensen A, Espevik T et al. Compartmentalization of TNF and IL-6 in meningitis and septic shock. Med Inflamm 1993; 2: 23-5.
40. Brandtzaeg P, Kierulf P, Gaustad P et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989; 159: 195-204.
41. van Deuren M, Brandtzaeg P, van der Meer J. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 2000; 13: 144-66.